Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Can-Fite BioPharma (NYSE American: CANF) announced that its research on Namodenoson's liver protective effects will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium. The company is currently conducting a pivotal Phase 3 multinational registrational trial for advanced liver cancer treatment. Notably, Namodenoson has shown remarkable results in one HCC patient who has remained cancer-free for over 8 years through a compassionate use program. The drug demonstrates dual benefits: anti-cancer activity and liver-protective effects, including anti-steatosis, anti-inflammatory, anti-fibrotic, and anti-ischemic properties. The protective mechanism works through adiponectin protein, which provides liver-, cardio-, and neuro-protective effects.
Can-Fite BioPharma (NYSE American: CANF) ha annunciato che la sua ricerca sugli effetti protettivi del Namodenosone sul fegato sarà presentata al Simposio Gastrointestinale sui Tumori ASCO 2025. Attualmente, l'azienda sta conducendo un trial registrativo multinazionale di fase 3 per il trattamento del carcinoma epatico avanzato. È particolarmente importante sottolineare che il Namodenosone ha mostrato risultati straordinari in un paziente con HCC che è rimasto libero dal cancro per oltre 8 anni grazie a un programma di uso compassionevole. Il farmaco dimostra benefici duali: attività anti-cancro ed effetti protettivi sul fegato, inclusi effetti anti-steatosi, anti-infiammatori, anti-fibrotici e anti-ischemici. Il meccanismo protettivo agisce attraverso la proteina adiponectina, che fornisce effetti protettivi sul fegato, sul cuore e sul sistema nervoso.
Can-Fite BioPharma (NYSE American: CANF) anunció que su investigación sobre los efectos protectores del Namodenosón en el hígado se presentará en el Simposio Gastrointestinal de Cáncer ASCO 2025. La compañía está llevando a cabo un ensayo clínico multinacional pivotal de fase 3 para el tratamiento del cáncer de hígado avanzado. Es notable que el Namodenosón ha mostrado resultados extraordinarios en un paciente con HCC que ha permanecido libre de cáncer durante más de 8 años a través de un programa de uso compasivo. El medicamento demuestra beneficios duales: actividad anticancerígena y efectos protectores del hígado, incluyendo propiedades antiesteatósicas, antiinflamatorias, antifibrosas y antiisquémicas. El mecanismo protector actúa a través de la proteína adiponectina, que proporciona efectos protectores para el hígado, el corazón y el sistema nervioso.
Can-Fite BioPharma (NYSE American: CANF)는 나모데노손의 간 보호 효과에 대한 연구를 2025 ASCO 위장관 암 심포지엄에서 발표한다고 발표했습니다. 현재 회사는 진행성 간암 치료를 위한 3상 다국가 등록 시험을 수행하고 있습니다. 특히, 나모데노손은 HCC 환자 한 명에서 놀라운 결과를 보여주었으며, 그 환자는 연민의 사용 프로그램을 통해 8년 이상 암이 없습니다. 이 약물은 항암 작용과 간 보호 효과, 즉 항지방증, 항염증, 항섬유증 및 항허혈 작용 등 이중 혜택을 보여줍니다. 보호 메커니즘은 아디포넥틴 단백질을 통해 작용하며, 이는 간, 심장 및 신경 보호 효과를 제공합니다.
Can-Fite BioPharma (NYSE American: CANF) a annoncé que sa recherche sur les effets protecteurs du Namodenoson sur le foie sera présentée lors du symposium ASCO sur les cancers gastro-intestinaux 2025. La société mène actuellement un essai clinique réglementaire multinational de phase 3 pour le traitement du cancer du foie avancé. Il convient de noter que le Namodenoson a montré des résultats remarquables chez un patient atteint de HCC qui est resté sans cancer pendant plus de 8 ans grâce à un programme d'utilisation compassionnelle. Ce médicament présente des avantages doubles : une activité anticancéreuse et des effets protecteurs du foie, y compris des propriétés anti-stéatosiques, anti-inflammatoires, anti-fibrotiques et anti-ischémiques. Le mécanisme protecteur agit grâce à la protéine adiponectine, qui offre des effets protecteurs pour le foie, le cœur et le système nerveux.
Can-Fite BioPharma (NYSE American: CANF) gab bekannt, dass die Forschung zu den leberschützenden Eigenschaften von Namodenoson beim ASCO-Gastrointestinal-Krebs-Symposium 2025 präsentiert wird. Das Unternehmen führt derzeit eine lebenswichtige multilaterale Phase-3-Registrierungsstudie zur Behandlung von fortgeschrittenem Leberkrebs durch. Bemerkenswert ist, dass Namodenoson bei einem HCC-Patienten bemerkenswerte Ergebnisse gezeigt hat, der seit über 8 Jahren krebsfrei ist, dank eines Programms für einen mitfühlenden Einsatz. Das Medikament zeigt doppelte Vorteile: antitumorale Aktivität und leberschützende Wirkungen, einschließlich anti-steatotischer, entzündungshemmender, antifibrotischer und antiischämischer Eigenschaften. Der schützende Mechanismus wirkt über das Adiponektin-Protein, das leber-, herz- und neuroprotektive Wirkungen bietet.
- Drug candidate Namodenoson demonstrated complete cancer clearance in one HCC patient, maintaining cancer-free status for 8+ years
- Unique dual benefit: combines anti-cancer activity with liver-protective effects
- Drug can be safely administered to advanced disease patients, unlike competitors that cause liver toxicity
- Phase 3 trial still ongoing with no conclusive efficacy data yet
- Single patient success case may not be representative of broader efficacy
Insights
The acceptance of Namodenoson's liver protective mechanism data at ASCO's Gastrointestinal Cancers Symposium, while prestigious, represents a routine scientific presentation rather than a material development that would significantly impact CANF's market position or valuation. The highlighted 8-year cancer-free case study, while promising, is anecdotal evidence from a single patient and cannot be extrapolated to broader efficacy claims.
The ongoing Phase III trial represents the critical value driver for CANF, but this announcement doesn't provide new data about enrollment progress or interim results. The liver-protective mechanism through adiponectin, while scientifically interesting, was previously known and doesn't constitute new market-moving information.
For a micro-cap biotech with a
- Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium
- Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study
Ramat Gan, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address Oncology and Inflammatory diseases, today announced that its work titled “The Liver Protective Effect of the anti-Cancer Drug Candidate Namodenoson is Mediated via Adiponectin” will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium to take place at San Francisco & On Line, January 23-25.
Currently, Namodenoson is being evaluated in a pivotal Phase 3 multinational registrational trial for the treatment of advanced liver cancer (Hepatocellular Carcinoma; HCC). Interestingly, Namodenoson has also completely cleared cancer in an HCC patient who was enrolled in Can-Fite’s Phase 2b HCC trial. The patient continues to be treated through a compassionate use program in Romania, where she remains cancer-free for more than 8 years following her first dose of Namodenoson.
The uniqueness of Namodenoson is that beyond its anti-cancer activity, it also induces a liver-protective effect. The latter is manifested by anti-steatosis, anti-inflammatory, anti-fibrotic, and anti-ischemic effects in the liver. Can-Fite researchers also found that the molecular mechanism of the protective effect is mediated via adiponectin protein, a positive cytokine released by adipocytes and endothelial cells in the body, known to induce liver-, cardio-, and neuro-protective effects.
Namodenoson has received significant acknowledgment in the scientific and medical communities, as evidenced by the numerous peer-reviewed publications and conferences, in which it has been published and presented.
“Our Phase 3 registrational trial is designed to treat patients who have tried, yet not benefitted from the few other FDA-approved HCC treatments on the market today. In distinction from these drugs which induce liver toxicity on top of their anti-cancer effect, Namodenoson has the advantage of having a liver-protective effect and therefore can be administered to patients with advanced disease,” stated Can-Fite CSO & Chairperson Dr. Pnina Fishman. We are hopeful that Namodenoson, with its liver-protective properties, can safely prolong life for advanced liver cancer patients.”
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson was evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of MASH a Phase III trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: https://www.canfite.com/.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 28, 2024 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
+972-3-9241114
FAQ
What are the key benefits of Can-Fite's (CANF) Namodenoson drug for liver cancer?
What stage is CANF's Namodenoson in clinical trials for liver cancer?
How long has the longest-treated patient been cancer-free using CANF's Namodenoson?
When will CANF present Namodenoson's liver protective effect data at ASCO?
How does CANF's Namodenoson protect the liver?
